ICAD Inc
ICAD3.870USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
105.19MMarket Cap
LossP/E TTM
More Details of ICAD Inc Company
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.
ICAD Inc Info
Ticker SymbolICAD
Company nameICAD Inc
IPO dateDec 13, 1984
CEOMs. Dana R. Brown
Number of employees66
Security typeOrdinary Share
Fiscal year-endDec 13
Address98 Spit Brook Rd Ste 100
CityNASHUA
Stock exchangeEuronext Paris
CountryUnited States of America
Postal code03062-5737
Phone16038825200
Websitehttps://www.icadmed.com/
Ticker SymbolICAD
IPO dateDec 13, 1984
CEOMs. Dana R. Brown
Company Executives of ICAD Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Eric Lonnqvist
Mr. Eric Lonnqvist
Chief Financial Officer
Chief Financial Officer
1.40K
-85.88%
Ms. Dana R. Brown
Ms. Dana R. Brown
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Michael John Doyle
Mr. Michael John Doyle
Independent Director
Independent Director
--
-100.00%
Mr. Andrew H. (Andy) Sassine
Mr. Andrew H. (Andy) Sassine
Independent Director
Independent Director
--
--
Dr. Rakesh Patel, M.D.
Dr. Rakesh Patel, M.D.
Independent Director
Independent Director
--
-100.00%
Mr. Mark Koeniguer
Mr. Mark Koeniguer
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Jonathan Go
Mr. Jonathan Go
Chief Technology Officer
Chief Technology Officer
--
-100.00%
Dr. Hedvig Hricak, M.D., Ph.D.
Dr. Hedvig Hricak, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Susan Alyson Wood, Ph.D.
Dr. Susan Alyson Wood, Ph.D.
Independent Director
Independent Director
--
-100.00%
John Nesbett
John Nesbett
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Eric Lonnqvist
Mr. Eric Lonnqvist
Chief Financial Officer
Chief Financial Officer
1.40K
-85.88%
Ms. Dana R. Brown
Ms. Dana R. Brown
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Michael John Doyle
Mr. Michael John Doyle
Independent Director
Independent Director
--
-100.00%
Mr. Andrew H. (Andy) Sassine
Mr. Andrew H. (Andy) Sassine
Independent Director
Independent Director
--
--
Dr. Rakesh Patel, M.D.
Dr. Rakesh Patel, M.D.
Independent Director
Independent Director
--
-100.00%
Mr. Mark Koeniguer
Mr. Mark Koeniguer
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q1
FY2024
FY2024Q3
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Subscription term licenses
1.78M
36.62%
Services and support
1.63M
33.44%
Products and perpetual licenses
1.25M
25.54%
Cloud subscriptions
214.00K
4.39%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Subscription term licenses
1.78M
36.62%
Services and support
1.63M
33.44%
Products and perpetual licenses
1.25M
25.54%
Cloud subscriptions
214.00K
4.39%
Shareholding Stats
Updated: Mon, Aug 18
Updated: Mon, Aug 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.40%
Schonfeld Strategic Advisors LLC
3.35%
Parkman Healthcare Partners LLC
2.85%
First Eagle Investment Management, L.L.C.
2.64%
Renaissance Technologies LLC
2.39%
Other
84.38%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.40%
Schonfeld Strategic Advisors LLC
3.35%
Parkman Healthcare Partners LLC
2.85%
First Eagle Investment Management, L.L.C.
2.64%
Renaissance Technologies LLC
2.39%
Other
84.38%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
0.37%
Other
99.63%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
117
9.75M
35.51%
+1.19M
2025Q1
121
10.21M
37.40%
+750.16K
2024Q4
119
7.73M
29.11%
-2.98M
2024Q3
123
8.12M
30.78%
-3.87M
2024Q2
135
8.40M
31.86%
-4.23M
2024Q1
165
8.42M
32.23%
-5.19M
2023Q4
173
9.77M
37.34%
-5.29M
2023Q3
181
9.87M
37.88%
-5.69M
2023Q2
189
9.43M
37.34%
-7.63M
2023Q1
202
11.14M
44.13%
-7.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
--
0%
--
--
First Eagle Investment Management, L.L.C.
--
0%
-145.58K
-100.00%
Renaissance Technologies LLC
--
0%
-306.30K
-100.00%
Credit Industriel et Commercial SA
--
0%
+450.00K
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
+4.00K
-100.00%
Geode Capital Management, L.L.C.
--
0%
+2.37K
-100.00%
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Dimensional US Core Equity 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
Dimensional US Core Equity 1 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ICAD Inc?
The top five shareholders of ICAD Inc are:
The Vanguard Group, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
First Eagle Investment Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
Renaissance Technologies LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Credit Industriel et Commercial SA holds 0.00 shares, accounting for 0.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 0.00 shares, accounting for 0.00% of the total shares.
The Vanguard Group, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
First Eagle Investment Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
Renaissance Technologies LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Credit Industriel et Commercial SA holds 0.00 shares, accounting for 0.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of ICAD Inc?
The top three shareholder types of ICAD Inc are:
The Vanguard Group, Inc.
Schonfeld Strategic Advisors LLC
Parkman Healthcare Partners LLC
The Vanguard Group, Inc.
Schonfeld Strategic Advisors LLC
Parkman Healthcare Partners LLC
How many institutions hold shares of ICAD Inc (ICAD)?
As of 2025Q2, 117 institutions hold shares of ICAD Inc, with a combined market value of approximately 9.75M, accounting for 35.51% of the total shares. Compared to 2025Q1, institutional shareholding has increased by -1.89%.
What is the biggest source of revenue for ICAD Inc?
In FY2025Q1, the Subscription term licenses business generated the highest revenue for ICAD Inc, amounting to 1.78M and accounting for 36.62% of total revenue.
